CYP3A4 and mature T-cell and NK-cell non-Hodgkin lymphoma: To test whether CYP3A could influence PTCL treatment outcome, its expression levels were compared with the patient clinical response and survival, and it was observed that a high CYP3A4 expression was significantly associated with a lower complete remission rate.